RecruitingPsoriatic ArthritisOverweight or Obesity

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

Eligible age

18+ yrs

Accepts

All genders

Locations

17 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with active PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.

Sponsor: Eli Lilly and Company

You may qualify if…

✓ Have a diagnosis of active psoriatic arthritis (PsA) as defined by a rheumatologist or other healthcare professional (HCP) experienced in treating PsA.
✓ Body Mass Index (BMI) of 30 kilograms per meter squared (kg/m²) or greater (obesity) or 27 kg/m2 to \<30 kg/m² (overweight) in the presence of at least 1 weight-related comorbid condition (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease).
✓ Who have been treated with ixekizumab for approximately 3 months (±1 month) prior to decision to add tirzepatide.
✓ Must be able to initiate tirzepatide (Day 0) within 30 days of treatment decision (baseline or screening).

You may not qualify if…

✕ Have currently received ixekizumab for more than 4 months or less than 2 months.
✕ Had any exposure to tirzepatide or other glucagon-like peptide-1 (GLP-1) receptor agonist (for example, dulaglutide, liraglutide, or semaglutide).
✕ Are currently enrolled in any other clinical study.
✕ Have a known hypersensitivity to any component of tirzepatide.
✕ Have a personal or family history of medullary thyroid cancer.
✕ Have multiple endocrine neoplasia type 2.
✕ Have type 1 diabetes mellitus.
✕ Have a history of chronic or acute pancreatitis at any time before screening.